Trial Profile

Safety and efficacy of lamivudine and telbivudine in preventing hepatitis B mother-to-child transmission: A retrospective cohort study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 26 Feb 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lamivudine (Primary) ; Telbivudine (Primary)
Indications Hepatitis B
Focus Therapeutic Use

Most Recent Events

26 Feb 2021 New trial record
01 Jan 2020 Primary endpoint of mother to child transmission MTCT rate was defined by HBsAg seropositivity or HBV DNA positivity at 7 to 12 months postpartum (Lamivudin and telbivudine versus control group) has been met, according to Results published in the BioMed Research International.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com